PCM
XLO icon

Prelude Capital Management’s Xilio Therapeutics XLO Stock Holding History

Prelude Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Buy
+11,600
New +$96.9K 0.01% 1097
2024
Q2 		– Sell
-2,107
Closed -$31.9K – 1539
2024
Q1 		$31.9K Buy
+2,107
New +$20.3K ﹤0.01% 1268

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Prelude Capital Management's XLO Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 11,600 shares worth $111K. The stake represents 0.01% of the portfolio and ranks #1097 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in XLO as recently as Q1 2024.

Prelude Capital Management first reported a position in XLO in Q1 2024 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Prelude Capital Management held 11,600 shares of Xilio Therapeutics worth $111K as of Q2 2026.
  • Xilio Therapeutics was a new Prelude Capital Management position in Q2 2026.
  • Xilio Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1097 holding.
  • Prelude Capital Management first reported a position in Xilio Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.